Last $305.40 USD
Change Today -1.34 / -0.44%
Volume 1.9M
BIIB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

biogen idec inc (BIIB) Snapshot

Open
$307.00
Previous Close
$306.74
Day High
$307.64
Day Low
$302.45
52 Week High
03/19/14 - $358.89
52 Week Low
12/17/13 - $270.27
Market Cap
72.1B
Average Volume 10 Days
1.6M
EPS TTM
$10.34
Shares Outstanding
236.2M
EX-Date
--
P/E TM
29.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOGEN IDEC INC (BIIB)

biogen idec inc (BIIB) Details

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn’s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company’s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

6,850 Employees
Last Reported Date: 02/6/14
Founded in 1985

biogen idec inc (BIIB) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $745.2K
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Executive Vice President of Research & Develo...
Total Annual Compensation: $766.8K
Executive Vice President of Pharmaceutical Op...
Total Annual Compensation: $625.6K
Compensation as of Fiscal Year 2013.

biogen idec inc (BIIB) Key Developments

Biogen Idec and Swedish Orphan Biovitrum AB Announce European Medicines Agency's Validation of Elocta(Tm) (Rfviiifc) Marketing Authorisation Application for Review

Biogen Idec and Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) of EloctaTM (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. The validation of the MAA initiates the EMA's review process. Elocta is the European trade name for rFVIIIFc, also known as EloctateTM [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the U.S., Canada, and Australia, where it is approved for the treatment of hemophilia A. Eloctate is the first recombinant clotting factor VIII therapy with prolonged circulation to provide protection from bleeding episodes with the potential for an extended interval between prophylactic injections. The regulatory application included results from the pivotal, Phase 3 clinical study, A-LONG that examined the efficacy, safety and pharmacokinetics of rFVIIIFc in males 12 years of age and older with severe haemophilia A and from the Phase 3 clinical study, Kids A-LONG that evaluated the efficacy and safety of rFVIIIFc in children with haemophilia A under 12 years of age. Biogen Idec and Sobi are collaborators in the development and commercialization of Eloctate/Elocta for haemophilia A. Sobi has an opt-in right to take over final development and commercialisation of Elocta for the Sobi territories (Europe, North Africa, Russia and most Middle Eastern markets). Biogen Idec leads development for Eloctate/Elocta, has manufacturing rights, and has commercialisation rights in North America and all other regions in the world excluding the Sobi territories.

Biogen Idec. Announces Executive Changes

Biogen Idec announced that two leading neuroscientists have joined the company to advance its research in neurodegenerative diseases. Christopher Henderson, Ph.D., joins as vice president, Neurology. Richard Ransohoff, M.D., joins as senior research fellow, Neuroimmunology. The addition of these top researchers bolsters Biogen Idec's discovery engine.

Biogen Idec Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Earnings Guidance for 2014

Biogen Idec Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenues were $2,511.4 million against $1,827.8 million last year. Income from operations was $1,152.6 million against $684.5 million last year. Income before income tax expense and equity in loss of investee, net of tax was $1,136.3 million against $679.9 million last year. Net income attributable to Biogen Idec Inc. was $856.9 million or $3.62 per diluted share against $487.6 million or $2.05 per diluted share last year. Non-GAAP earnings per share – diluted were $3.80 against $2.35 last year. Non-GAAP net income attributable to Biogen Idec Inc. was $899.6 million against $561.1 million last year. For the nine months, total revenues were $7,062.6 million against $4,966.3 million last year. Income from operations was $2,812.7 million against $1,857.6 million last year. Income before income tax expense and equity in loss of investee, net of tax was $2,795.6 million against $1,828.1 million last year. Net income attributable to Biogen Idec Inc. was $2,051.3 million or $8.64 per diluted share against $1,405.0 million or $5.89 per diluted share last year. Non-GAAP earnings per share – diluted were $9.75 against $6.62 last year. Non-GAAP net income attributable to Biogen Idec Inc. was $2,315.6 million against $1,579.3 million last year. The company has updated its full year of 2014 financial guidance. This updated guidance consists of the following components: revenue growth is expected to be approximately 38% to 41% compared to 2013, unchanged from prior guidance. GAAP diluted EPS is expected to be between $12.00 and $12.10. Non-GAAP diluted EPS is expected to be between $13.45 and $13.55, an increase over prior guidance primarily due to updated business development expectations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB:US $305.40 USD -1.34

BIIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,709 JPY -13.50
Celgene Corp $111.07 USD +0.09
Novo Nordisk A/S kr266.60 DKK +0.10
Shire PLC 4,501 GBp +33.00
Thermo Fisher Scientific Inc $127.88 USD +0.47
View Industry Companies
 

Industry Analysis

BIIB

Industry Average

Valuation BIIB Industry Range
Price/Earnings 29.0x
Price/Sales 8.0x
Price/Book 6.9x
Price/Cash Flow 24.6x
TEV/Sales 7.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.